Clinical Trial Update: Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine [Phase 4]

View source ↗

Summary

Phase 4 trial assessed immunogenicity and safety of a tetanus-diphtheria vaccine given with a 13-valent pneumococcal conjugate vaccine; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pneumococcal Infection
• Tetanus

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)
• Tetanus Diphtheria Vaccine (tetanus/diphtheria toxoid vaccine)

Snippet

Sponsor: Korea University Guro Hospital | Conditions: Tetanus, Diphtheria | Phase 4 | Status: COMPLETED